Squalene versus cholesterol: Which is the best nanocarrier for the delivery to cells of the anticancer drug gemcitabine?
Authors:
- Arnaud PeramoAPArnaud Peramo
- Simona MuraSMSimona Mura
- Semen O. YesylevskyySYSemen O. Yesylevskyy
- Bruno CardeyBCBruno Cardey
- Dunja SobotDSDunja Sobot
- Stephanie DenisSDStephanie Denis
- Christophe RamseyerCRChristophe Ramseyer
- Didier DesmaëleDDDidier Desmaële
- Patrick CouvreurPCPatrick Couvreur
Open Access
- 20 March 2018
- journal article
- conference paper
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Chimie
- Vol. 21 (10) , 974-986
Abstract
It has been previously shown that the linkage of the anticancer drug gemcitabine (Gem) to the squalene (SQ), a natural lipid precursor of the cholesterol biosynthesis, allowed the resulting bioconjugates to spontaneously self-assemble as nanoparticles (NPs) with improved pharmacological activity. We show here that when the squalene moiety was replaced by the cholesterol and the conjugation performed through a carbamate linker, although rather stable nanoparticles were obtained, the in vitro anticancer activity in the human breast cancer cell line MDA-MB-231 was completely abolished. This was attributed to reduced enzymatic accessibility toward the carbamate linker, which may hamper the gemcitabine release. A lower propensity of incorporation into the plasma cell membrane, which was revealed by molecular simulations, may also play a role in lower activity of cholesterol derivative.Keywords
Funding Information
- European Community's Seventh Framework Programme (249835)
- CNRS
- French Ministry of Research
- European Union's Horizon 2020
This publication has 28 references indexed in Scilit:
- A Squalene-Based Nanomedicine for Oral Treatment of Colon CancerCancer Research, 2017
- Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug deliveryNature Communications, 2017
- Cancer nanomedicines: oversold or underappreciated?Expert Opinion on Drug Delivery, 2016
- Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injuryNature Nanotechnology, 2014
- A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activityProceedings of the National Academy of Sciences, 2014
- Cancer nanomedicines: So many papers and so few drugs!Advanced Drug Delivery Reviews, 2013
- Self-Assembled Squalenoylated Penicillin Bioconjugates: An Original Approach for the Treatment of Intracellular InfectionsACS Nano, 2012
- Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer NanomedicineThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Squalenoyl Nanomedicines as Potential TherapeuticsNano Letters, 2006
- Nanocapsule formation by interfacial polymer deposition following solvent displacementInternational Journal of Pharmaceutics, 1989